Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Following Huge Thing: 5 Progressive Tech New businesses - 2Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives
- 3Computerized Domains d: A Survey of \Vivid Undertakings\ Computer generated Reality Game
- 4Pick Your Favored method of transportation
- 5Arctic is again the hottest it's been in 125 years, with record-low sea ice, NOAA report says
- My Pioneering Excursion: Building a Startup
- Russia Creates New Military Branch Dedicated To Drone Warfare
- Two policemen injured at religious youth protest in Jerusalem marking Ahuvia Sandak's death
- South Carolina's measles outbreak reaches 434 cases
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- Japan prepares to restart world's biggest nuclear plant, 15 years after Fukushima
- Figure out How to Keep up with and Clean Your Brilliant Bed for Ideal Execution
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- Undeniably popular Historical centers: Where Craftsmanship and History Meet
